Loading...

William Sandborn

Title(s)Chief, Gastroenterology
SchoolHealth Sciences
Address9500 Gilman Drive #0956
La Jolla CA 92093
Phone858-657-5331
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Fellowship1993Mayo Clinic
    Intern/Residency1990Loma Linda Univ Medical Center
    MD1987Loma Linda University
    BA1983Southern College

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. Inflamm Bowel Dis. 2020 Jun 27. Dulai PS, Jairath V, Zou G, Stitt LW, Khanna R, Sandborn WJ, Feagan BG, Singh S. PMID: 32592481.
      View in: PubMed   Mentions:    Fields:    
    2. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 Jun 23. Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. PMID: 32573825.
      View in: PubMed   Mentions:    Fields:    
    3. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 Jun 22. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 32585306.
      View in: PubMed   Mentions:    Fields:    
    4. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020 Jun 15. Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. PMID: 32553149.
      View in: PubMed   Mentions:    Fields:    
    5. Estimates of the Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 Jun 08. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32526341.
      View in: PubMed   Mentions:    Fields:    
    6. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. Aliment Pharmacol Ther. 2020 Jun; 51(11):1209-1210. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 32424928.
      View in: PubMed   Mentions:    Fields:    
    7. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther. 2020 May 22. Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR. PMID: 32445184.
      View in: PubMed   Mentions:    Fields:    
    8. Microsimulation Model to Determine the Cost Effectiveness of Treat to Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 May 10. Dulai PS, Sandborn WJ, Murphy J. PMID: 32437872.
      View in: PubMed   Mentions:    Fields:    
    9. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020 May 07. Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. PMID: 32384283.
      View in: PubMed   Mentions:    Fields:    
    10. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With infliximab. Clin Gastroenterol Hepatol. 2020 May 03. Casteele NV, Jairath V, Jeyarajah J, Dulai P, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. PMID: 32376505.
      View in: PubMed   Mentions:    Fields:    
    11. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Aliment Pharmacol Ther. 2020 May; 51(10):997-998. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 32338784.
      View in: PubMed   Mentions:    Fields:    
    12. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. Am J Gastroenterol. 2020 05; 115(5):738-745. Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, D'Haens G. PMID: 31850931.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    13. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Apr 26. Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. PMID: 32348905.
      View in: PubMed   Mentions:    Fields:    
    14. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020 Jun; 51(11):1031-1038. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32329532.
      View in: PubMed   Mentions:    Fields:    
    15. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020 Jun; 51(11):1047-1066. Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. PMID: 32319120.
      View in: PubMed   Mentions: 1     Fields:    
    16. Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients. Nutrients. 2020 Apr 10; 12(4). Chey W, Sandborn W, Ritter AJ, Foyt H, Azcarate-Peril MA, Savaiano DA. PMID: 32290344.
      View in: PubMed   Mentions:    Fields:    
    17. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020 Apr; 72(4):561-576. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. PMID: 30875456.
      View in: PubMed   Mentions: 1     Fields:    
    18. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Mar 17. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. PMID: 32179906.
      View in: PubMed   Mentions:    Fields:    
    19. Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: A translational medicine program. J Crohns Colitis. 2020 Mar 11. Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. PMID: 32161949.
      View in: PubMed   Mentions:    Fields:    
    20. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis. 2020 Mar 04; 26(4):515-523. George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. PMID: 31504528.
      View in: PubMed   Mentions:    Fields:    
    21. Progression of Elderly-Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-based Cohort Studies. Clin Gastroenterol Hepatol. 2020 Mar 03. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. PMID: 32142940.
      View in: PubMed   Mentions:    Fields:    
    22. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis. 2020 Feb 27. Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. PMID: 32105310.
      View in: PubMed   Mentions:    Fields:    
    23. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020 03; 579(7797):123-129. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC. PMID: 32103176.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    24. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 Feb 26. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960.
      View in: PubMed   Mentions:    Fields:    
    25. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020 Jun; 158(8):2139-2149.e14. Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. PMID: 32092309.
      View in: PubMed   Mentions:    Fields:    
    26. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Feb 13. Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041.
      View in: PubMed   Mentions:    Fields:    
    27. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020 Jun; 158(8):2123-2138.e8. Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. PMID: 32044319.
      View in: PubMed   Mentions:    Fields:    
    28. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 Jan 30. Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. PMID: 32003126.
      View in: PubMed   Mentions:    Fields:    
    29. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020 01; 42(1):157-174.e4. Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. PMID: 31982148.
      View in: PubMed   Mentions:    Fields:    
    30. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020 Apr; 5(4):393-405. Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. PMID: 31954438.
      View in: PubMed   Mentions:    Fields:    
    31. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Jan 13. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. PMID: 31945470.
      View in: PubMed   Mentions:    Fields:    
    32. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313. Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. PMID: 31644790.
      View in: PubMed   Mentions:    Fields:    
    33. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastroenterol. 2020 Jan 04. Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. PMID: 31902071.
      View in: PubMed   Mentions:
    34. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. PMID: 31158271.
      View in: PubMed   Mentions: 5     Fields:    
    35. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020 03; 51(5):553-564. Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F. PMID: 31867766.
      View in: PubMed   Mentions:    Fields:    
    36. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Dec 07. Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. PMID: 31816446.
      View in: PubMed   Mentions:    Fields:    
    37. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020 02; 51(4):435-445. Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. PMID: 31755121.
      View in: PubMed   Mentions: 1     Fields:    
    38. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 Nov 21. Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. PMID: 31748806.
      View in: PubMed   Mentions:    Fields:    
    39. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):550-561. Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. PMID: 31711921.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    40. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. 2020 02; 158(3):515-526.e10. D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. PMID: 31711925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. Genome Biol. 2019 10 31; 20(1):226. Sanders JG, Nurk S, Salido RA, Minich J, Xu ZZ, Zhu Q, Martino C, Fedarko M, Arthur TD, Chen F, Boland BS, Humphrey GC, Brennan C, Sanders K, Gaffney J, Jepsen K, Khosroheidari M, Green C, Liyanage M, Dang JW, Phelan VV, Quinn RA, Bankevich A, Chang JT, Rana TM, Conrad DJ, Sandborn WJ, Smarr L, Dorrestein PC, Pevzner PA, Knight R. PMID: 31672156.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    42. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol. 2020 May; 18(6):1268-1279. Nguyen NH, Singh S, Sandborn WJ. PMID: 31676360.
      View in: PubMed   Mentions:    Fields:    
    43. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 01; 51(2):271-280. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 31660640.
      View in: PubMed   Mentions: 1     Fields:    
    44. Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Inflamm Bowel Dis. 2019 10 18; 25(11):1773-1779. Schwartz DA, Tagarro I, Carmen Díez M, Sandborn WJ. PMID: 31216573.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 10 18; 25(11):1828-1837. Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. PMID: 31039246.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis. 2019 10 18; 25(11):1854-1861. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. PMID: 31050734.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 11; 50(10):1068-1076. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 31599001.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 01; 158(1):76-94.e2. Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. PMID: 31593701.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    49. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C. PMID: 31553833.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    50. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Jul; 18(8):1760-1768.e1. Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. PMID: 31546056.
      View in: PubMed   Mentions:    Fields:    
    51. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. PMID: 30726897.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 10; 50(8):848-857. Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. PMID: 31483522.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):537-549.e10. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. PMID: 31493397.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    54. Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. Clin Gastroenterol Hepatol. 2019 Aug 29. Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR. PMID: 31473359.
      View in: PubMed   Mentions:    Fields:    
    55. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):562-572.e12. Sandborn WJ, Baert F, Danese S, Krznaric Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. PMID: 31470005.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    56. Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Aug 27. Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. PMID: 31470176.
      View in: PubMed   Mentions: 1     Fields:    
    57. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 May; 18(5):1121-1132.e2. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. PMID: 31442599.
      View in: PubMed   Mentions:    Fields:    
    58. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 08 20; 25(9):1532-1540. Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. PMID: 30753466.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019 Aug; 79(12):1321-1335. Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. PMID: 31317509.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology. 2019 11; 157(5):1233-1244.e5. Hindryckx P, Jairath V, Zou G, Feagan BG, Sandborn WJ, Stoker J, Khanna R, Stitt L, van Viegen T, Shackelton LM, Taylor SA, Santillan C, Mearadji B, D'Haens G, Richard MP, Panes J, Rimola J. PMID: 31336124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 10; 157(4):1019-1031.e7. Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. PMID: 31279870.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    62. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. PMID: 31279871.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    63. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1. Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. PMID: 31228441.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Correction: Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1011. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 31033518.
      View in: PubMed   Mentions:    Fields:    
    65. Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1010. Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 31033520.
      View in: PubMed   Mentions:    Fields:    
    66. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019; 5(1):e000942. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. PMID: 31245056.
      View in: PubMed   Mentions:
    67. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis. 2019 May 27; 13(6):725-734. Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. PMID: 30753371.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 Feb; 18(2):424-431.e7. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. PMID: 31108227.
      View in: PubMed   Mentions:    Fields:    
    69. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019 05; 114(5):733-745. Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. PMID: 30694863.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol. 2019 12; 17(13):2634-2643. Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, Eckmann L, Barrett KE, Chang JT, Sandborn WJ. PMID: 31009791.
      View in: PubMed   Mentions: 1     Fields:    
    71. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Aliment Pharmacol Ther. 2019 06; 49(11):1401-1409. Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G. PMID: 30983024.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    72. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019 04; 114(4):630-639. Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S. PMID: 30865012.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci. 2019 09; 64(9):2478-2488. Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. PMID: 30923985.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    74. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019 05; 49(9):1188-1194. Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V. PMID: 30891808.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    75. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019; 10:212. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30930775.
      View in: PubMed   Mentions:
    76. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Jan; 18(1):69-81.e3. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. PMID: 30876964.
      View in: PubMed   Mentions: 2     Fields:    
    77. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019 Feb 01; 13(2):172-181. Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. PMID: 30285104.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    78. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 10; 25(2):410-420. Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 30295781.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 01 10; 25(2):270-282. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30165490.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    80. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 11; 17(12):2497-2505.e1. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. PMID: 30625408.
      View in: PubMed   Mentions: 2     Fields:    
    81. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. PMID: 30203005.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    82. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflamm Bowel Dis. 2019 01 01; 25(1):163-171. Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. PMID: 29982631.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    83. Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113(12):696. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 30390030.
      View in: PubMed   Mentions:    Fields:    
    84. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2527-2542. Hemperly A, Sandborn WJ, Vande Casteele N. PMID: 29788338.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    85. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019 03; 156(4):946-957.e18. Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. PMID: 30472236.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    86. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 07; 17(8):1541-1550. Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. PMID: 30476584.
      View in: PubMed   Mentions: 6     Fields:    
    87. Serum Concentrations of 7a-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2722-2730.e4. Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. PMID: 30448597.
      View in: PubMed   Mentions:    Fields:    
    88. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018 Nov 09; 12(10):1158-1169. Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C. PMID: 29917064.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    89. Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient. Front Microbiol. 2018; 9:2559. Fang X, Monk JM, Nurk S, Akseshina M, Zhu Q, Gemmell C, Gianetto-Hill C, Leung N, Szubin R, Sanders J, Beck PL, Li W, Sandborn WJ, Gray-Owen SD, Knight R, Allen-Vercoe E, Palsson BO, Smarr L. PMID: 30425690.
      View in: PubMed   Mentions:
    90. Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019 11; 68(11):2101-2102. Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. PMID: 30366909.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1814-1821.e1. Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. PMID: 30613004.
      View in: PubMed   Mentions: 2     Fields:    
    92. Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 02; 64(2):382-390. Ahmad W, Nguyen NH, Boland BS, Dulai PS, Pride DT, Bouland D, Sandborn WJ, Singh S. PMID: 30361807.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    93. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019 02; 89(2):215-237. Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ. PMID: 30365985.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):63-70. Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. PMID: 30343116.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    95. Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2366-2376. Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. PMID: 29889233.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    96. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    97. Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 03; 17(4):709-718.e7. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 30012429.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 07; 17(8):1533-1540.e2. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 30268561.
      View in: PubMed   Mentions: 2     Fields:    
    99. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1. Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. PMID: 30267864.
      View in: PubMed   Mentions: 2     Fields:    
    100. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019 01; 17(2):218-230. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. PMID: 30240894.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    101. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis. 2018 09 15; 24(10):2278-2284. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29788260.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    102. Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proc Natl Acad Sci U S A. 2018 09 25; 115(39):E9192-E9200. Garcia-Carbonell R, Wong J, Kim JY, Close LA, Boland BS, Wong TL, Harris PA, Ho SB, Das S, Ernst PB, Sasik R, Sandborn WJ, Bertin J, Gough PJ, Chang JT, Kelliher M, Boone D, Guma M, Karin M. PMID: 30209212.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    103. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. Hanauer SB, Sandborn WJ, Lichtenstein GR. PMID: 30195449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Aug 29; 12(9):1053-1066. Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C. PMID: 29917070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 10; 155(4):1045-1058. Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. PMID: 29909019.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    106. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029. Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. PMID: 29767728.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    107. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 12; 16(12):1847-1850.e1. Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. PMID: 30149146.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    108. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 11; 3(11):742-753. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. PMID: 30122356.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    109. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 08 16; 24(9):1876-1882. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. PMID: 29668916.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. PMID: 30076171.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    111. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis. 2018 Jul 30; 12(8):930-938. Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. PMID: 29697818.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    112. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis. 2018 Jul 30; 12(8):883-895. Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG. PMID: 29726939.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):671-680. Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. PMID: 30056030.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    114. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688. Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. PMID: 30022113.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    115. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018 10; 155(4):1008-1011.e8. Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. PMID: 29981298.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    116. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 09; 113(9):1345. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 29946178.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    117. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 08; 113(8):1197-1205. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 29925913.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    118. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018 06; 113(6):883-889. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29867171.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    119. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 09; 155(3):687-695.e10. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. PMID: 29857091.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    120. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 25; 12(6):635-643. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. PMID: 29370397.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    121. Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 05 18; 24(6):1316-1320. Fumery M, Patel NS, Boland BS, Dulai PS, Singh S, Sandborn WJ. PMID: 29697797.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    122. Obesity and response to anti-tumor necrosis factor-a agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0195123. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. PMID: 29771924.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    123. A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. Gastroenterol Hepatol (N Y). 2018 May; 14(5 Suppl 2):1-12. Sandborn WJ, Abreu MT, Dubinsky MC. PMID: 29991933.
      View in: PubMed   Mentions:
    124. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 04 27; 12(5):631. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 29566131.
      View in: PubMed   Mentions:    Fields:    
    125. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflamm Bowel Dis. 2018 04 23; 24(5):932-942. Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM. PMID: 29668919.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    126. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018 08; 88(2):360-369.e2. Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L, Bloom S, Pardi DS, Gionchetti P, Lindsay J, Travis S, Hart A, Silverberg MS, Feagan BG, D'Haens GR, Jairath V. PMID: 29660321.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    127. Ustekinumab IV 6?mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. Am J Gastroenterol. 2018 04; 113(4):627-629. Park S, Evans E, Sandborn WJ, Boland B. PMID: 29610516.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    128. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87. Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. PMID: 29601825.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    129. Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2018 03 28; 12(4):510. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 29385425.
      View in: PubMed   Mentions: 1     Fields:    
    130. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 29596987.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    131. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 03 19; 24(4):871-876. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV. PMID: 29509927.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    132. Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 03 19; 24(4):916-923. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29562273.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    133. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16(1):129-146. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. PMID: 29411220.
      View in: PubMed   Mentions:
    134. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018 08; 16(8):1284-1292.e30. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29474966.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    135. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. PMID: 29462395.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    136. Tracking Human Gut Microbiome Changes Resulting from a Colonoscopy. Methods Inf Med. 2017; 56(6):442-447. Smarr L, Hyde ER, McDonald D, Sandborn WJ, Knight R. PMID: 29582916.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    137. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. PMID: 29409871.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    138. Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis. 2018 Jan 24; 12(2):167-177. Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. PMID: 29028958.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    139. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating ß7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis. 2018 Jan 24; 12(2):188-196. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. PMID: 28961770.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    140. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. PMID: 29345635.
      View in: PubMed   Mentions: 2     Fields:    
    141. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018 01 18; 24(2):277-285. Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. PMID: 29361090.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    142. Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. Inflamm Bowel Dis. 2018 01 18; 24(2):440-449. Jairath V, Ordas I, Zou G, Panes J, Stoker J, Taylor SA, Santillan C, Horsthuis K, Samaan MA, Shackelton LM, Stitt LW, Hindryckx P, Khanna R, Sandborn WJ, D'Haens G, Feagan BG, Levesque BG, Rimola J. PMID: 29361096.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    143. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology. 2018 Mar; 286(3):776-799. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA. PMID: 29319414.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    144. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018 Mar; 154(4):1172-1194. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA. PMID: 29329905.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    145. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. PMID: 28961959.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    146. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 12 04; 11(12):1510. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28453665.
      View in: PubMed   Mentions:    Fields:    
    147. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 12; 56(12):1513-1523. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. PMID: 28353055.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    148. Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2018 01; 154(1):37-45. Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. PMID: 29122544.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    149. Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. PMID: 29095427.
      View in: PubMed   Mentions: 1     Fields:    
    150. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018 12 23; 390(10114):2779-2789. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. PMID: 29096949.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    151. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017 Nov; 112(11):1658-1669. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Bredenoord AJ, Jairath V. PMID: 29039850.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    152. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 10; 67(10):1824-1835. Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. PMID: 28982740.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    153. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest Endosc. 2017 12; 86(6):962-971. Kaltenbach T, Sandborn WJ. PMID: 28987547.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    154. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. Am J Gastroenterol. 2017 10; 112(10):1621. Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. PMID: 28978958.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    155. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 09 08; 9:CD011572. Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28886205.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    156. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):603-626. Deepak P, Sandborn WJ. PMID: 28838418.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    157. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 28843356.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    158. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 08 03; 377(5):496-7. Sandborn WJ, Su C, Panes J. PMID: 28767341.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    159. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 28333288.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    160. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2017 Jul 21; 7:CD012351. Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. PMID: 28731502.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    161. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 07; 23(7):1047-1056. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. PMID: 28410341.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    162. Eldelumab [anti-interferon-?-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis. 2017 Jul 01; 11(7):811-819. Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. PMID: 28333187.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    163. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28333362.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    164. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 03; 16(3):343-356.e3. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. PMID: 28625817.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    165. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open. 2017 06 09; 7(6):e016146. Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V. PMID: 28601837.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    166. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. PMID: 28527704.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    167. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J. PMID: 28467869.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    168. Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 06; 112(6):975. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28417993.
      View in: PubMed   Mentions: 3     Fields:    
    169. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 04 29; 389(10080):1699-1709. Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. PMID: 28411872.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    170. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 01; 11(4):425-434. Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. PMID: 27815351.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    171. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683798.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    172. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683800.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    173. Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017 Mar 01; 11(suppl_2):S567-S575. Peyrin-Biroulet L, Lopez A, Sandborn W. PMID: 27660343.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    174. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 06; 66(6):1049-1059. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. PMID: 28209624.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    175. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Oct; 112(10):1584-1592. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28071654.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    176. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2017 01; 23(1):97-106. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. PMID: 27930408.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    177. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2017 Jun; 15(6):850-856. Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. PMID: 28013116.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    178. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2018 03; 67(3):441-446. Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn WJ, Pardi DS. PMID: 27965284.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    179. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27916678.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    180. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):110-121. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. PMID: 27899815.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    181. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P. PMID: 27959607.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCTClinical Trials
    182. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. PMID: 27585411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    183. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018 01; 67(1):61-69. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Lebwohl B, Leffler DA, Jairath V. PMID: 27799282.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    184. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. PMID: 27833391.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    185. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. PMID: 27780886.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    186. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):374-388.e4. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. PMID: 27780712.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    187. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 12; 111(12):1806-1815. Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. PMID: 27670599.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    188. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. Dulai PS, Sandborn WJ, Gupta S. PMID: 27679553.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    189. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. Dulai PS, Sandborn WJ. PMID: 27461274.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    190. Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 08 25; 375(8):e17. Sandborn WJ, Feagan BG. PMID: 27557326.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    191. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 12; 32(12):1937-1941. Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. PMID: 27494777.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    192. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 08; (8):CD010642. Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. PMID: 27501379.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    193. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 02; 11(2):246-255. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 27487793.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    194. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. PMID: 27400222.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    195. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6. Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. PMID: 27416045.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    196. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2. Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. PMID: 27464592.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    197. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017 Jan; 11(1):35-46. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. PMID: 27440869.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    198. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 27385400.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    199. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. Sandborn WJ. PMID: 27489526.
      View in: PubMed   Mentions:
    200. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 07; 22(7):1737-43. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. PMID: 27306074.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    201. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 08; 111(8):1147-55. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. PMID: 27296941.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    202. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. PMID: 27189916.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    203. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A. PMID: 27144850.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    204. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 10; 14(10):1439-44. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 27155552.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    205. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 05; 111(5):746-8. Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. PMID: 27151126.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    206. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016 Apr 28; 7:e168. Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. PMID: 27124701.
      View in: PubMed   Mentions: 6     Fields:    
    207. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. PMID: 26835982.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    208. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 07; 32(7):1233-41. Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. PMID: 26986449.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    209. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. PMID: 27018491.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    210. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P. PMID: 26946343.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    211. Reply. Gastroenterology. 2016 Apr; 150(4):1039. Jharap B, Colombel JF, Sandborn WJ. PMID: 26926449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    212. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 05; 66(5):839-851. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. PMID: 26893500.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    213. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. PMID: 26850690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    214. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. PMID: 26822833.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    215. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. PMID: 26746169.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    216. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. PMID: 26721935.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    217. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L. PMID: 26646934.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    218. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. PMID: 26540276.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    219. The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. Reiss M, Sandborn WJ. PMID: 26589873.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    220. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015 Nov 23; (11):CD001176. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. PMID: 26593456.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    221. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. PMID: 26618431.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    222. Association Between Response to Etrolizumab and Expression of Integrin aE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-87.e9. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. PMID: 26522261.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    223. Development and validation of a histological index for UC. Gut. 2017 01; 66(1):50-58. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. PMID: 26475633.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    224. Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn WJ, Rutgeerts P. PMID: 26086596.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    225. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. PMID: 26386854.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    226. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. PMID: 26376350.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    227. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 07; 386(10006):1825-34. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG. PMID: 26342731.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    228. Reply: To PMID 24036054. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. Sandborn WJ, Bouguen G. PMID: 26247165.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    229. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-97.e1-3. Rutgeerts P, Reinisch W, Colombel JF, Sandborn WJ, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. PMID: 26234693.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    230. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. PMID: 26094251.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    231. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. Vande Casteele N, Sandborn WJ. PMID: 26077557.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    232. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. PMID: 26071941.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    233. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. Vaughn BP, Sandborn WJ, Cheifetz AS. PMID: 25590953.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    234. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. PMID: 25989338.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    235. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. PMID: 26005012.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    236. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. PMID: 25964225.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    237. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ. PMID: 25956538.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    238. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 07; 65(7):1119-25. Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. PMID: 25935574.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    239. New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. Sandborn WJ. PMID: 27482177.
      View in: PubMed   Mentions:
    240. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. PMID: 25908718.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    241. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. PMID: 25735646.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    242. Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. PMID: 25837708.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    243. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 25884529.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    244. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 26491415.
      View in: PubMed   Mentions:
    245. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ. PMID: 25581826.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    246. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. PMID: 25731159.
      View in: PubMed   Mentions: 127     Fields:    Translation:HumansAnimalsCells
    247. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. PMID: 25667416.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    248. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. PMID: 25545378.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    249. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. PMID: 25644096.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    250. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. PMID: 25661014.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    251. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. PMID: 25222660.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    252. Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. Sandborn WJ. PMID: 25531358.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    253. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. PMID: 25192499.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    254. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. PMID: 25137418.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    255. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. PMID: 25299543.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    256. Reproducibility of histological assessments of disease activity in UC. Gut. 2015 Nov; 64(11):1765-73. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, MacDonald JK, Vandervoort MK, Samaan MA, Geboes K, Valasek MA, Pai R, Langner C, Riddell R, Harpaz N, Sewitch M, Peterson M, Stitt LW, Levesque BG. PMID: 25360036.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    257. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015 Oct; 64(10):1539-45. Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR, Rutgeerts PJ, Gils A, Sandborn WJ, Vermeire S, Feagan BG. PMID: 25336114.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    258. A phase II study of laquinimod in Crohn's disease. Gut. 2015 Aug; 64(8):1227-35. D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG. PMID: 25281416.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    259. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014 Oct; 20(10):1850-61. Khanna R, Bouguen G, Feagan BG, D'Haens G, Sandborn WJ, Dubcenco E, Baker KA, Levesque BG. PMID: 25029615.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    260. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015 Jan; 148(1):52-63.e3. Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus EV, Louis E, Panés J, Schölmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, Fiorino G, Herzog M, Kamm MA, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini GE, Zagdanski AM, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel JF, Cosnes J. PMID: 25241327.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    261. Factors associated with short- and long-term outcomes of therapy for Crohn's disease. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):539-547.e2. Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F. PMID: 25245629.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    262. An overview of magnetic resonance enterography for Crohn's disease. Dig Dis Sci. 2014 Sep; 59(9):2040-9. Pola S, Santillan C, Levesque BG, Feagan BG, Sandborn WJ. PMID: 24659238.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    263. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014 Dec; 147(6):1296-1307.e5. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W. PMID: 25173754.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    264. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov; 109(11):1771-80. Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB. PMID: 25155227.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    265. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015 Jan; 148(1):37-51.e1. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. PMID: 25127678.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    266. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. Clin Gastroenterol Hepatol. 2015 Apr; 13(4):731-8.e1-6; quiz e41. Yadav S, Dave M, Edakkanambeth Varayil J, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sweetser SR, Melton LJ, Sandborn WJ, Loftus EV. PMID: 25130936.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    267. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014 Aug; 20(8):1465-71. Samaan MA, Mosli MH, Sandborn WJ, Feagan BG, D'Haens GR, Dubcenco E, Baker KA, Levesque BG. PMID: 24831558.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    268. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2014 Aug; 10(8):478-489. Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 28845139.
      View in: PubMed   Mentions:
    269. Crohn's disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014 Sep; 147(3):702-5. Sandborn WJ. PMID: 25046160.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    270. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE. PMID: 24989100.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    271. Systematic review: Monotherapy with antitumour necrosis factor a agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014 Dec; 63(12):1843-53. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. PMID: 24970900.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    272. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014 Sep; 43(3):603-17. Boland BS, Sandborn WJ, Chang JT. PMID: 25110261.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    273. Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1894-6. Vande Casteele N, Sandborn WJ. PMID: 24951843.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    274. Studies in human intestinal tissues: is it time to reemphasize research in human immunology? Gastroenterology. 2014 Jul; 147(1):26-30. Chang JT, Sandborn WJ, Ernst PB. PMID: 24877864.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    275. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. PMID: 24859203.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    276. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014 Jul; 109(7):994-1004. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. PMID: 24842338.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    277. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26; 384(9940):309-18. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Tew GW, Luca D, Tang MT, Diehl L, Eastham-Anderson J, De Hertogh G, Perrier C, Egen JG, Kirby JA, van Assche G, Rutgeerts P. PMID: 24814090.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    278. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. PMID: 24713173.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    279. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014 Apr; 16(4):378. Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. PMID: 24595615.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    280. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014 Mar; 20(3):564-75. Mosli MH, Feagan BG, Sandborn WJ, D'haens G, Behling C, Kaplan K, Driman DK, Shackelton LM, Baker KA, Macdonald JK, Vandervoort MK, Geboes K, Levesque BG. PMID: 24412993.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    281. Non-cirrhotic portal hypertension due to 6-mercaptopurine use for Crohn's disease. Dig Dis Sci. 2014 Jul; 59(7):1642-4. Pola S, Boland BS, Lin GY, Kuo A, Sandborn WJ. PMID: 24535249.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    282. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1246-56.e6. Williet N, Sandborn WJ, Peyrin-Biroulet L. PMID: 24534550.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    283. Taking a closer look at IBD. Gut. 2014 Feb; 63(2):e1. Egan LJ, Sandborn W. PMID: 24381262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    284. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014 Feb; 20(2):231-9. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24351660.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    285. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Sep; 12(9):1485-93.e2. Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W. PMID: 24480677.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansAnimalsCTClinical Trials
    286. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014 Feb; 109(2):212-23. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. PMID: 24394749.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    287. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014 Apr; 146(4):941-9. Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. PMID: 24361468.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    288. Outcomes of computed tomography and magnetic resonance enterography in clinical practice of inflammatory bowel disease. Dig Dis Sci. 2014 Apr; 59(4):838-49. Patel NS, Pola S, Muralimohan R, Zou GY, Santillan C, Patel D, Levesque BG, Sandborn WJ. PMID: 24323180.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    289. IBD: Measuring what counts--endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol. 2014 Jan; 11(1):9-10. Khanna R, Levesque BG, Sandborn WJ. PMID: 24296581.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    290. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jun; 12(6):978-85. Bouguen G, Levesque BG, Pola S, Evans E, Sandborn WJ. PMID: 24246770.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    291. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):423-31.e1. Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X. PMID: 24184736.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    292. Azathioprine-induced neuro-psychiatric disorders. J Crohns Colitis. 2014 Feb; 8(2):180. Bouguen G, Evans E, Sandborn WJ. PMID: 24103346.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    293. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):110-118.e3. Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J. PMID: 24067881.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    294. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. PMID: 24036054.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansPHPublic Health
    295. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014 Jan; 63(1):88-95. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. PMID: 23974954.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    296. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. PMID: 23964932.
      View in: PubMed   Mentions: 306     Fields:    Translation:HumansCTClinical Trials
    297. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A. PMID: 23964933.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansCTClinical Trials
    298. Is there still a role for thiopurines in Crohn's disease? Gastroenterology. 2013 Oct; 145(4):714-6. Rogler G, Sandborn WJ. PMID: 23973853.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    299. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013 Nov; 145(5):978-986.e5. Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ. PMID: 23954314.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    300. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013 Aug; 19(9):1858-66. Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 23660997.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    301. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 23891974.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    302. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 Mar; 12(3):414-22.e5. Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. PMID: 23856361.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    303. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul; 19(8):1700-9. Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, Thakkar RB. PMID: 23665965.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    304. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis. 2013 Jul; 19(8):1645-53. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. PMID: 23598817.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    305. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):96-109.e1. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P. PMID: 23770005.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    306. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. PMID: 23730956.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    307. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):85-95; quiz e14-5. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P. PMID: 23735746.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    308. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun; 19(7):1384-9. Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. PMID: 23535248.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    309. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013 May; 108(5):857-8. Pola S, Fahmy M, Evans E, Tipps A, Sandborn WJ. PMID: 23644970.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    310. Crohn's disease complicated by strictures: a systematic review. Gut. 2013 Jul; 62(7):1072-84. Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. PMID: 23626373.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    311. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr; 19(5):1004-9. Sinakos E, Samuel S, Enders F, Loftus EV, Sandborn WJ, Lindor KD. PMID: 23502353.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    312. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. PMID: 23511031.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    313. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology. 2013 Jul; 145(1):149-157.e2. Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JWD, Rutgeerts P, Munkholm P, Mittmann U, King D, Wong CJ, Zou G, Donner A, Shackelton LM, Gilgen D, Nelson S, Vandervoort MK, Fahmy M, Loftus EV, Panaccione R, Travis SP, Van Assche GA, Vermeire S, Levesque BG. PMID: 23528626.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    314. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis. 2013 Dec; 7(12):958-67. Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R. PMID: 23517933.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    315. Biosimilars in IBD: hope or expectation? Gut. 2013 Jun; 62(6):803-7. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Löwenberg M, Jairath V, Travis SP, Sandborn WJ, Feagan BG, D'Haens GR. PMID: 23503043.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    316. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin. 2013 May; 29(5):483-93. Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB. PMID: 23438483.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    317. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar; 63(3):442-50. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY. PMID: 23461895.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    318. Symptomatic overlap between microscopic colitis and irritable bowel syndrome: a prospective study. Inflamm Bowel Dis. 2013 Mar; 19(3):550-3. Abboud R, Pardi DS, Tremaine WJ, Kammer PP, Sandborn WJ, Loftus EV. PMID: 23380937.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    319. Cecal patch manifest as an inflammatory pseudopolyp and characterized by chromoendoscopy. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):E57-8. Fahmy M, Shabaik A, Sandborn WJ. PMID: 22552963.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    320. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):677-82. Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, Pizarro TT, de Zoeten EF, Stappenbeck TS, Plevy SE, Abraham C, Nusrat A, Jobin C, McCole DF, Siegel CA, Higgins PD, Herfarth HH, Hyams J, Sandborn WJ, Loftus EV, Kappelman MD, Lewis JD, Parkos CA, Sartor RB. PMID: 23448796.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    321. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014 Mar; 63(3):433-41. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. PMID: 23436336.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    322. Reply: budesonide. Gastroenterology. 2013 Mar; 144(3):e23-4. Sandborn WJ, Travis S, Ballard D. PMID: 23357061.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    323. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013 Jun; 11(6):654-66. Velayos FS, Kahn JG, Sandborn WJ, Feagan BG. PMID: 23357488.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    324. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013 Feb; 108(2):256-9. Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, Kammer PP, Sandborn WJ, Loftus EV, Pardi DS. PMID: 23295275.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansPHPublic Health
    325. Deep remission: a new concept? Dig Dis. 2012; 30 Suppl 3:107-11. Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. PMID: 23295700.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    326. The future of inflammatory bowel disease therapy: where do we go from here? Dig Dis. 2012; 30 Suppl 3:140-4. Sandborn WJ. PMID: 23295705.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    327. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012 Dec; 107(12):1770-6. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. PMID: 23211844.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    328. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan; 37(2):204-13. Sandborn WJ, Colombel JF, D'Haens G, Van Assche G, Wolf D, Kron M, Lazar A, Robinson AM, Yang M, Chao JD, Thakkar R. PMID: 23173821.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    329. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 24847181.
      View in: PubMed   Mentions:
    330. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG. PMID: 23075178.
      View in: PubMed   Mentions: 215     Fields:    Translation:HumansCTClinical Trials
    331. Infliximab versus ciclosporin in severe ulcerative colitis. Lancet. 2012 Dec 01; 380(9857):1887-8. Levesque BG, Sandborn WJ. PMID: 23063315.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    332. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan; 108(1):90-8. Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. PMID: 23044768.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    333. Infliximab for Crohn's disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013 Mar; 58(3):797-806. Seminerio JL, Loftus EV, Colombel JF, Thapa P, Sandborn WJ. PMID: 23053885.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    334. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology. 2012 Dec; 143(6):1461-9. D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M. PMID: 23000597.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    335. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov; 107(11):1693-701. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 22945286.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    336. Crohn's disease. Lancet. 2012 Nov 03; 380(9853):1590-605. Baumgart DC, Sandborn WJ. PMID: 22914295.
      View in: PubMed   Mentions: 384     Fields:    Translation:Humans
    337. Ulcerative colitis. Lancet. 2012 Nov 03; 380(9853):1606-19. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. PMID: 22914296.
      View in: PubMed   Mentions: 244     Fields:    Translation:Humans
    338. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16; 367(7):616-24. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. PMID: 22894574.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCTClinical Trials
    339. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):49-54.e1. Samuel S, Bruining DH, Loftus EV, Thia KT, Schroeder KW, Tremaine WJ, Faubion WA, Kane SV, Pardi DS, de Groen PC, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 22902762.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    340. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012 Sep; 107(9):1409-22. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ. PMID: 22890223.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    341. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012 Nov; 143(5):1218-1226.e2. Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED. PMID: 22892337.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    342. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012 Dec; 10(12):1315-1325.e4. Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera-Nieves J, Chang JT, Evans E, Docherty M, Talamini M, Sandborn WJ. PMID: 22835577.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    343. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Oct; 10(10):1079-87; quiz e85-6. Ordás I, Feagan BG, Sandborn WJ. PMID: 22813440.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    344. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012 Jul; 107(7):1051-63. Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, Cornillie F, Colombel JF. PMID: 22613901.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    345. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. Am J Gastroenterol. 2012 Jul; 107(7):1064-77. D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P. PMID: 22565161.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    346. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012 May; 107(5):794-5. Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. PMID: 22552250.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    347. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis. Gastroenterology. 2012 Aug; 143(2):356-64.e1. Sands BE, Sandborn WJ, Creed TJ, Dayan CM, Dhanda AD, Van Assche GA, Greguš M, Sood A, Choudhuri G, Stempien MJ, Levitt D, Probert CS. PMID: 22549092.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    348. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. PMID: 22504093.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    349. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1253-9. Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, Zinsmeister AR, Sandborn WJ. PMID: 22503995.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    350. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012 Apr; 91(4):635-46. Ordás I, Mould DR, Feagan BG, Sandborn WJ. PMID: 22357456.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimals
    351. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 2012 May; 142(5):1102-1111.e2. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G. PMID: 22326435.
      View in: PubMed   Mentions: 101     Fields:    Translation:Humans
    352. Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012 Feb; 6 Suppl 2:S224-34. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. PMID: 22463929.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    353. Mucosal healing with infliximab: results from the active ulcerative colitis trials. Gastroenterol Hepatol (N Y). 2012 Feb; 8(2):117-9. Sandborn WJ. PMID: 22485079.
      View in: PubMed   Mentions:
    354. IBD in 2011: Advances in IBD management--towards a tailored approach. Nat Rev Gastroenterol Hepatol. 2012 Jan 10; 9(2):70-2. Pineton de Chambrun GP, Sandborn WJ. PMID: 22230905.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    355. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):400-4. Nguyen DL, Sandborn WJ, Loftus EV, Larson DW, Fletcher JG, Becker B, Mandrekar J, Harmsen WS, Bruining DH. PMID: 22155562.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    356. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. PMID: 22083024.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    357. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb; 142(2):257-65.e1-3. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar RB. PMID: 22062358.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansCTClinical Trials
    358. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012 Feb; 18(2):349-58. Colombel JF, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. PMID: 22021134.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    359. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011 Dec; 60(12):1754-63. Ordás I, Feagan BG, Sandborn WJ. PMID: 21997558.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    360. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. PMID: 21997563.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    361. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis. 2012 Jul; 18(7):1240-8. Cipriano LE, Levesque BG, Zaric GS, Loftus EV, Sandborn WJ. PMID: 21928375.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    362. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011 Dec; 106(12):2070-7; quiz 2078. Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. PMID: 21894226.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    363. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011 Sep; 106(9):1594-602; quiz 1593, 1603. Van Assche G, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J, Siegel CA, Sandborn WJ, Travis SP, Colombel JF. PMID: 21844919.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    364. Setting a high threshold for noninferiority: mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis. 2012 Apr; 18(4):795-6. Levesque BG, Sandborn WJ. PMID: 21739537.
      View in: PubMed   Mentions:    Fields:    
    365. Henoch-schönlein purpura in an adult mimicking Crohn's disease and pyoderma gangrenosum. Dig Dis Sci. 2011 Jul; 56(7):2205-6. Samuel S, Loftus EV, Sandborn WJ. PMID: 21249449.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    366. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. PMID: 21723220.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    367. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012 Feb; 61(2):241-7. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF. PMID: 21646246.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    368. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):670-678.e3. Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. PMID: 21642014.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    369. Computed tomography enterography detects intestinal wall changes and effects of treatment in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011 Aug; 9(8):679-683.e1. Bruining DH, Loftus EV, Ehman EC, Siddiki HA, Nguyen DL, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Sandborn WJ, Fletcher JG. PMID: 21621641.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    370. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. PMID: 21484965.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    371. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. PMID: 21472012.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansPHPublic Health
    372. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012 Feb; 18(2):275-83. Garrity-Park M, Loftus EV, Sandborn WJ, Smyrk TC. PMID: 21425209.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    373. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012 Feb; 18(2):226-35. Kisiel JB, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21416564.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    374. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011 Apr; 106(4):674-84. Billioud V, Sandborn WJ, Peyrin-Biroulet L. PMID: 21407178.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    375. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. PMID: 21407183.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansPHPublic Health
    376. Why innovation in inflammatory bowel disease drug development will impact your practice. Clin Gastroenterol Hepatol. 2011 Mar; 9(3):211-3. Sandborn WJ. PMID: 21338946.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    377. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis. 2011 Mar; 17(3):778-86. Siddiki H, Fletcher JG, Hara AK, Kofler JM, McCollough CH, Fidler JL, Guimaraes L, Huprich JE, Sandborn WJ, Loftus EV, Mandrekar J, Bruining DH. PMID: 20848546.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    378. Perianal Crohn's disease findings other than fistulas in a population-based cohort. Inflamm Bowel Dis. 2012 Jan; 18(1):43-8. Peyrin-Biroulet L, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 21351216.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    379. Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence. Inflamm Bowel Dis. 2012 Feb; 18(2):219-25. Bruining DH, Siddiki HA, Fletcher JG, Sandborn WJ, Fidler JL, Huprich JE, Mandrekar JN, Harmsen WS, Evans PE, Faubion WA, Hanson KA, Ingle SB, Pardi DS, Schroeder KW, Tremaine WJ, Loftus EV. PMID: 21337477.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    380. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2011 May; 9(5):395-9. Bruining DH, Sandborn WJ. PMID: 21277392.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    381. Reversal of multifocal low- and high-grade dysplasia in patients with an ileoanal pouch. Gastroenterology. 2011 Mar; 140(3):1107-8; author reply 1108-9. Levesque BG, Hanson KA, Sandborn WJ. PMID: 21272556.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    382. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. PMID: 21209123.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    383. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011 Jan; 17(1):141-51. Sandborn WJ, Colombel JF, Schreiber S, Plevy SE, Pollack PF, Robinson AM, Chao J, Mulani P. PMID: 20848500.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    384. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis. 2011 Jan; 17(1):105-11. Thia K, Faubion WA, Loftus EV, Persson T, Persson A, Sandborn WJ. PMID: 20629100.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    385. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224. Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. PMID: 21157441.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    386. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. PMID: 21104734.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    387. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun; 17(6):1415-22. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. PMID: 21560202.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    388. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. PMID: 21045814.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    389. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010 Nov; 16(11):1912-21. Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 20848486.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    390. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut. 2010 Nov; 59(11):1485-92. Sandborn WJ, Colombel JF, Frankel M, Hommes D, Lowder JN, Mayer L, Plevy S, Stokkers P, Travis S, Van Assche G, Baumgart DC, Targan SR. PMID: 20947884.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    391. Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2011 Jun; 17(6):1443-4. Levesque BG, Sandborn WJ. PMID: 21560204.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    392. State-of-the-art: Immunosuppression and biologic therapy. Dig Dis. 2010; 28(3):536-42. Sandborn WJ. PMID: 20926883.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    393. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis. 2011 Jun; 17(6):1257-64. Thia KT, Loftus EV, Pardi DS, Kane SV, Faubion WA, Tremaine WJ, Schroeder KW, Harmsen SW, Zinsmeister AR, Sandborn WJ. PMID: 20878712.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    394. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg. 2010 Dec; 14(12):1859-65; discussion 1865-6. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW. PMID: 20872084.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    395. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan; 17(1):471-8. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20725943.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    396. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010 Oct; 139(4):1147-55. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. PMID: 20637205.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    397. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD001176. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. PMID: 20556748.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    398. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):688-695.e2. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. PMID: 20451663.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    399. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 Apr 15; 362(15):1383-95. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. PMID: 20393175.
      View in: PubMed   Mentions: 529     Fields:    Translation:Humans
    400. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010 May; 105(5):1142-9. Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. PMID: 20389296.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    401. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. PMID: 20363366.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    402. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. PMID: 19714757.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    403. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010 Jul; 105(7):1574-82. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ. PMID: 20234346.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    404. How to avoid treating irritable bowel syndrome with biologic therapy for inflammatory bowel disease. Dig Dis. 2009; 27 Suppl 1:80-4. Sandborn WJ. PMID: 20203501.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    405. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010 Jul; 105(7):1610-9. Garrity-Park MM, Loftus EV, Sandborn WJ, Bryant SC, Smyrk TC. PMID: 20160714.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    406. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May; 105(5):1133-9. Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ. PMID: 20145610.
      View in: PubMed   Mentions: 96     Fields:    Translation:Humans
    407. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010 Feb; 59(2):141-7. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 20176633.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    408. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ. PMID: 20117244.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    409. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm Bowel Dis. 2010 Feb; 16(2):226-32. Guimarães LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, Sandborn WJ, Loftus EV, Pardi DS, McCollough CH. PMID: 19637359.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    410. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010 Apr; 8(4):357-63. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. PMID: 20096379.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimals
    411. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. PMID: 20064514.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    412. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg. 2010 Jan; 145(1):42-7. Malireddy K, Larson DW, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, Qin R, Gullerud RE, Cima RR, Wolff B, Dozois EJ. PMID: 20083753.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    413. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010 Jan; 16(1):15-22. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Kostanjsek N, Kamm MA, Hibi T, Lémann M, Stucki G, Colombel JF. PMID: 19610077.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    414. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010 Feb; 105(2):289-97. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. PMID: 19861953.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    415. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1599-604. D'Haens GR, Fedorak R, Lémann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Schölmerich J, Hanauer S, Sandborn WJ. PMID: 19653291.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    416. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. PMID: 19766640.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    417. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009 Sep; 15(9):1308-19. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. PMID: 19434735.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    418. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009 Sep; 15(9):1326-30. Ravi K, Chari ST, Vege SS, Sandborn WJ, Smyrk TC, Loftus EV. PMID: 19235915.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    419. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. PMID: 19408340.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    420. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol. 2009 Nov; 104(11):2768-73. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. PMID: 19672253.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    421. Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8):2097-9. Velayos FS, Sandborn WJ. PMID: 19661939.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    422. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. PMID: 19596014.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    423. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol. 2009 Jul; 193(1):113-21. Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, Johnson CD, Bruining DH, Loftus EV, Sandborn WJ, Pardi DS, Mandrekar JN. PMID: 19542402.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    424. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009 Oct; 104(10):2524-33. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. PMID: 19532125.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    425. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W. PMID: 19130617.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    426. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease. Clin Gastroenterol Hepatol. 2009 Oct; 7(10):1139. Peyrin-Biroulet L, Colombel JF, Sandborn WJ. PMID: 19465159.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    427. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009 May; 15(5):772-7. Hanson KA, Loftus EV, Harmsen WS, Diehl NN, Zinsmeister AR, Sandborn WJ. PMID: 19107782.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    428. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009 May; 104(5):1170-9. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. PMID: 19352339.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    429. Colectomy subtypes, follow-up surgical procedures, postsurgical complications, and medical charges among ulcerative colitis patients with private health insurance in the United States. Inflamm Bowel Dis. 2009 Apr; 15(4):566-75. Loftus EV, Friedman HS, Delgado DJ, Sandborn WJ. PMID: 19143006.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    430. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol. 2009 Apr; 104(4):868-76. Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. PMID: 19240707.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    431. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 19174807.
      View in: PubMed   Mentions: 220     Fields:    Translation:Humans
    432. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2009 Jan; 15(1):1-8. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. PMID: 18671232.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    433. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. PMID: 18668682.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    434. The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9(3):E69-77. Sandborn WJ. PMID: 19898267.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    435. Relationships between C-reactive protein concentration and genotype in healthy volunteers. Clin Chem Lab Med. 2009; 47(1):20-5. Jones J, Chen LS, Baudhuin L, Peterson S, Harmsen WS, Zinsmeister AR, McConnell J, Sandborn WJ. PMID: 19072030.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    436. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. PMID: 18786111.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    437. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008 Dec; 103(12):3167-82. Thia KT, Loftus EV, Sandborn WJ, Yang SK. PMID: 19086963.
      View in: PubMed   Mentions: 173     Fields:    Translation:Humans
    438. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis. 2008 Dec; 14(12):1701-6. Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV. PMID: 18623171.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    439. AGA Institute Future Trends Committee report: the future of gastroenterology training programs in the United States. Gastroenterology. 2008 Nov; 135(5):1764-89.e2. Wang TC, Cominelli F, Fleischer DE, Gordon JM, Glickman RM, Limsui D, McQuaid KR, Montrose M, Pasricha PJ, Powell DW, Rowe WA, Sandborn WJ, Todisco A. PMID: 19009690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    440. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008 Nov; 135(5):1442-7. Sandborn WJ. PMID: 18848556.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    441. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S232-3. Sandborn WJ. PMID: 18816658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    442. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1218-24. Jones J, Loftus EV, Panaccione R, Chen LS, Peterson S, McConnell J, Baudhuin L, Hanson K, Feagan BG, Harmsen SW, Zinsmeister AR, Helou E, Sandborn WJ. PMID: 18799360.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    443. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008 Nov; 135(5):1493-9. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. PMID: 18848553.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    444. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 Oct; 135(4):1130-41. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. PMID: 18706417.
      View in: PubMed   Mentions: 151     Fields:    Translation:Humans
    445. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet. 2008 Jul 05; 372(9632):67-81. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. PMID: 18603161.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    446. Certolizumab Pegol for Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2008 Jul; 4(7):467-8. Sandborn WJ. PMID: 21960919.
      View in: PubMed   Mentions:
    447. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2008 Aug; 103(8):2015-22. Peloquin JM, Pardi DS, Sandborn WJ, Fletcher JG, McCollough CH, Schueler BA, Kofler JA, Enders FT, Achenbach SJ, Loftus EV. PMID: 18564113.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    448. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008 Jul; 103(7):1737-45. Loftus EV, Delgado DJ, Friedman HS, Sandborn WJ. PMID: 18564126.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    449. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008 Aug; 68(2):255-66. Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, Tremaine WJ, Egan LJ, Faubion WA, Schroeder KW, Pardi DS, Hanson KA, Jewell DA, Barlow JM, Fidler JL, Huprich JE, Johnson CD, Harmsen WS, Zinsmeister AR, Sandborn WJ. PMID: 18513722.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    450. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008 Jun; 6(6):644-53. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. PMID: 18550004.
      View in: PubMed   Mentions: 114     Fields:    Translation:Humans
    451. Indeterminate colitis: a review of the concept--what's in a name? Inflamm Bowel Dis. 2008 Jun; 14(6):850-7. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH. PMID: 18213696.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    452. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. PMID: 18602921.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    453. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008 Apr 09; 299(14):1690-7. Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hébuterne X, Paré P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, Zou GY, Donner A, Rutgeerts P. PMID: 18398081.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansPHPublic Health
    454. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008 Apr; 42(4):338-44. Sandborn WJ. PMID: 18277908.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    455. Initial combination therapy in early Crohn's disease. Lancet. 2008 Feb 23; 371(9613):635-636. Sandborn WJ. PMID: 18295013.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    456. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008 Feb; 103(2):407-15. Garrity-Park MM, Loftus EV, Bryant SC, Sandborn WJ, Smyrk TC. PMID: 18289203.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    457. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008 Apr; 134(4):929-36. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. PMID: 18294633.
      View in: PubMed   Mentions: 183     Fields:    Translation:Humans
    458. Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(4):271-2. Sandborn WJ. PMID: 19107101.
      View in: PubMed   Mentions:    Fields:    
    459. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol. 2007 Dec; 102(12):2737-46. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. PMID: 18042106.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    460. Positioning biologic therapy for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2007 Dec; 9(6):521-7. Velayos FS, Sandborn WJ. PMID: 18377806.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    461. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ. PMID: 17567869.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    462. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis. 2007 Oct; 13(10):1266-70. Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn WJ, Loftus EV, Pemberton JH. PMID: 17567877.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    463. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007 Sep; 3(5):683-94. Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. PMID: 20477019.
      View in: PubMed   Mentions:    Fields:    
    464. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007 Sep; 13(9):1135-40. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. PMID: 17476675.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    465. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. PMID: 17920064.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    466. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. PMID: 17764676.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansPHPublic Health
    467. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):228-38. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. PMID: 17634458.
      View in: PubMed   Mentions: 203     Fields:    Translation:Humans
    468. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. PMID: 17634459.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    469. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. PMID: 17631151.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    470. A moveable feast. Clin Gastroenterol Hepatol. 2007 Jun; 5(6):646-7. Camilleri M, Sandborn WJ, Kolars JC, Murray JA, Poterucha JJ, Roberts L, Sinicrope FA, Wang KK. PMID: 17544990.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    471. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12; 369(9573):1641-57. Baumgart DC, Sandborn WJ. PMID: 17499606.
      View in: PubMed   Mentions: 392     Fields:    Translation:Humans
    472. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007 May; 204(5):956-62; discussion 962-3. Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV, Sandborn WJ, Wolff BG, Pemberton JH. PMID: 17481518.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    473. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. PMID: 17470824.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    474. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007 May; 132(5):1672-83. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ. PMID: 17484865.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    475. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007 Mar; 13(3):254-61. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. PMID: 17206702.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    476. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. PMID: 17324131.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    477. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007 Feb; 13(2):175-81. Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn WJ. PMID: 17206699.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    478. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007 Apr; 102(4):829-36. Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P, Sandborn WJ. PMID: 17222314.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    479. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007 Jan; 5(1):95-102. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. PMID: 17234558.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    480. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. Hanauer SB, Sandborn WJ. PMID: 17392632.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    481. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S23-35. Sandborn WJ. PMID: 17392636.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    482. Clinical perspectives in Crohn's disease: now and in the future. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 2:S1-2. Sandborn WJ. PMID: 17392634.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    483. A new treatment option for ulcerative colitis. Rev Gastroenterol Disord. 2007; 7(2):106-7. Sandborn WJ. PMID: 17597673.
      View in: PubMed   Mentions:    Fields:    
    484. Step-up versus top-down therapy in the treatment of ulcerative colitis. Gastroenterol Hepatol (N Y). 2007 Jan; 3(1):16-7. Sandborn WJ. PMID: 21960772.
      View in: PubMed   Mentions:
    485. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. PMID: 17258735.
      View in: PubMed   Mentions: 166     Fields:    Translation:Humans
    486. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006 Dec; 12(12):1093-100. Tung J, Loftus EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton LJ, Harmsen WS, Sandborn WJ, Faubion WA. PMID: 17119382.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    487. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007 Apr; 56(4):504-8. Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 17135309.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    488. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. PMID: 17241859.
      View in: PubMed   Mentions: 370     Fields:    Translation:HumansCTClinical Trials
    489. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):66-75; quiz 432-3. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. PMID: 17241860.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    490. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology. 2006 Dec; 241(3):787-95. Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV, Harmsen WS. PMID: 17032911.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    491. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bowel Dis. 2006 Aug; 12(8):708-11. Laing AW, Pardi DS, Loftus EV, Smyrk TC, Kammer PP, Tremaine WJ, Schleck CD, Harmsen WS, Zinsmeister AR, Melton LJ, Sandborn WJ. PMID: 16917225.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    492. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006 Aug; 12(8):669-76. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16917220.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    493. Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice. J Clin Gastroenterol. 2006 Aug; 40(7):587-91. Sands BE, Kilgore KM, Bloomfeld RS, Sandborn WJ. PMID: 16917398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    494. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. PMID: 16825929.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    495. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):888-93. Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M. PMID: 16797249.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    496. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006 Jun; 130(7):1941-9. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. PMID: 16762617.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    497. CLASSIC-I study the efficacy of adalimumab. Gastroenterology. 2006 May; 130(6):1929-30. Schreiber S, Sandborn WJ. PMID: 16697761.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    498. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May; 4(5):621-30. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. PMID: 16678077.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    499. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. PMID: 16606351.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    500. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology. 2006 Apr; 130(4):1039-46. Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, Sandborn WJ. PMID: 16618397.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    501. Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology. 2006 Feb; 238(2):505-16. Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV, Harmsen WS, Crownhart BS. PMID: 16436815.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    502. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placeb